Introduction
Gliomas can be classified into four pathological grades based on the 2007 World Health Organization (WHO) classification. Low-grade glioma refers to WHO grade I and II gliomas, the prognosis of which is better than that of high-grade gliomas (WHO grade III and IV). 1 Although the treatment of choice for gliomas has been extensively researched, current therapies generally remain incapable of significantly improving the prognosis and survival time of patients with gliomas. The main obstacle to treatment efficacy is our insufficient knowledge about the biological molecular mechanisms of malignant gliomas. 2 In recent years, microRNA (miRNA) has been recognized to play important roles in the post-transcription regulation of gene expressions. The miRNA-200 family is transcribed from two chromosomal locations: chromosome 1p36, which contains miRNA-200b, miRNA-200a, and miRNA-429, and chromosome 12p13, which contains miRNA-200c and miRNA-141. 3 Decreased expression of miRNA-200 has been proven in gastric, lung, endometrial, ovarian, and breast cancers. [4] [5] [6] [7] [8] MiRNA-200b is recognized as a crucial regulator of chemosensitivity, epithelial-mesenchymal transition, and the cell cycle. 9 Several recent studies have demonstrated lower expression of miRNA-200b in malignant glioma specimens and cell lines. [10] [11] [12] [13] [14] Peng et al reported that over-expression of miR-200b inhibited the colony formation and proliferation of glioma cells. 15 Oncogene-encoding CREB1, a significant transcription factor involved in the metastasis, survival, and proliferation of cancer cells, has been confirmed as a direct target-gene of miR-200b. They also demonstrated that CREB1 was present at high levels in glioma tissues and was inversely related to miR-200b expressions. CREB1's ectopic expressions suppressed the growth-suppressive phenotypes of glioma cells due to miR-200b. Nevertheless, the detailed relationship between miRNA-200b and the glioma WHO grade remains unclear and under discussion, partly because of the small sample sizes in previous studies and the potential heterogeneity among these studies. We performed the present meta-analysis to elucidate the more exact clinical implications of miRNA-200b in the pathological grading of gliomas. We also collected glioma samples and normal brain tissue samples to test the levels of miRNA-200b.
Methods search strategy, study selection, and data extraction
The ethics committee of Changzheng Hospital, Second Military Medical University reviewed and approved our research.
Two authors independently conducted computer searches of PubMed, Web of Knowledge, Embase, and Chinese National Knowledge Infrastructure (CNKI) to collect articles describing case-control studies related to the association between miRNA-200b and the risk of glioma. Search terms involved "microRNA-200", "glioma [MeSH]", "expression", and "grade". The relevant reference articles in the identified studies were reviewed to identify other potentially eligible publications. The inclusion and exclusion criteria are listed in Table 1 .
The two investigators independently extracted necessary data from all eligible publications according to the inclusion criteria listed in Table 1 . The following information was abstracted from each of the included articles: names of the authors, publication year, study population, journal name, mean age, patient numbers, histopathologic findings, test methods, WHO grades, and miRNA-200b level in surgical specimens. Disagreements between the two reviewers were resolved by a third investigator.
Data synthesis and analysis
We conducted the meta-analysis according to the PRISMA checklist and followed the guideline. Differences were expressed as odds ratios (ORs) with 95% CIs. L'Abbé plots, Cochran Q-tests, and I 2 tests (variations of OR attributable to heterogeneity) ( Table 2) were conducted to estimate the heterogeneity among the included studies. 16, 17 Subgroup analyses were not performed because of the limited number of included studies. If no significant heterogeneity among the studies was detected, a fixed-effects model was adopted. Otherwise, we used the random-effects model described by Laird and DerSimonian. Sensitivity analyses (Table 2) were conducted to assess the stability of the pooled results. 17 Publication bias was evaluated using contour-enhanced funnel plots 18 (Table 2) . Because only five studies were included, we did not perform a meta-regression analysis.
A P-value of <0.05 was considered statistically significant. Data analyses were conducted using STATA 12.0 (StataCorp LP, College Station, TX, USA) and Review Manager 5.3 software (Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark). SD was calculated from independent experiments. The PCR primers were designed as follows: miR-200b sense, 5′-GCG GCT AAT ACT GCC TGG TAA-3′, and reverse, 5′-GTG CAG GGT CCG AGG T-3′; U6 sense, 5′-CGC TTC GGC AGC ACA TAT ACT A-3′, and reverse, 5′-CGC TTC ACG AAT TTG CGT GTC A-3′.
statistical analysis
All computations were carried out using SPSS version 13.0 for Windows software (SPSS Inc., Chicago, IL, USA). Data were expressed as mean ± SD. The chi-squared test was used to assess miR-200b expression with respect to clinicopathological parameters. Differences were considered statistically significant when P was less than 0.05.
Results

search results and study characteristics
The literature search was conducted as presented in Figure 1 . A total of five articles finally met the inclusion criteria. [10] [11] [12] [13] [14] All five studies were performed in Asian populations. One was written in Chinese 14 and four were written in English. [10] [11] [12] [13] The baseline characteristics of the studies are shown in Table 3 . The miRNA-200b levels were measured using real-time PCR The i 2 index measures the extent of true heterogeneity dividing the difference between the result of the Q test and its df (k -1) by the Q value itself, and multiplied by 100. i 2 values of 25%, 50%, and 75% were used as evidence of low, moderate, and high heterogeneity, respectively. sensitivity analysis
To examine the stability of the pooled results a sensitivity analysis was performed using the one-at-a-time method, which involved omitting one study at a time and repeating the meta-analysis. If the omission of one study significantly changed the result, it implied that the result was sensitive to the studies included. Contour-enhanced funnel plot
Publication bias test
Visual inspection of the contour-enhanced funnel plots was used to assess potential publication bias. asymmetry in the plots, which may be due to studies missing on the lefthand side of the plot that represents low statistical significance, suggested publication bias. If studies were missing in the high statistical significance areas (on the right-hand side of the plot), the funnel asymmetry was not considered to be due to publication bias.
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Meta-analysis of relationship between miRna-200b and gliomas
All gliomas were divided into high grade (WHO grade III + IV) and low grade (WHO grade I+II) for the data analyses. In total, 244 patients with low-grade gliomas and 386 patients with high-grade gliomas were analyzed in this study. The points on the L'Abbé plot did not exhibit a linear distribution (Figure 2 ), suggesting heterogeneity among the included studies (Q=95.83, df=4, I 2 =95.8%, P<0.001). The heterogeneity was relatively high; therefore, we pooled the data using a random-effects model, which assumes that the data being analyzed are drawn from a hierarchy of different populations whose differences relate to that hierarchy, assisting in controlling for unobserved heterogeneity. As revealed in Figure 3A , the forest plot demonstrated that the expression of miR-200b was much higher in low-grade than high-grade gliomas. The integrated ORs suggested a significant negative correlation between the miRNA-200b expression level and the WHO glioma grade (OR, 0.070; 95% CI, 0.007-0.678; P=0.022). We also tested the correlation between the miRNA-200b level and sex, age, tumor size, and extent of resection. Figure 2B and C shows that the points on the L'Abbé plots basically exhibited a linear distribution, providing evidence of homogeneity among the studies and suggesting the rationality of using a fixed-effects model. The five studies involved 335 male and 295 female patients and 293 young and 337 old patients. No significant associations were found between the miRNA-200b level and either sex (OR, 1.029; 95% CI, 0.749-1.415; P=0.858) or age (OR, 1.048; 95% CI, 0.760-1.445; P=0.776) ( Figure  3B and C). Only two studies focused on tumor size and the extent of surgical resection, and no significant differences were detected (tumor size: OR, 0.715; 95% CI, 0.462-1.108; P=0.134 and extent of resection: OR, 1.072; 95% CI, 0.660-1.742; P=0.778) ( Figure 3D and E).
sensitivity analysis and publication bias
Each individual study was deleted one at a time to determine whether the study affected the pooled ORs. Our results showed that the ORs were not affected by omitting the included studies (Figure 2D-F) . Contour-enhanced funnel plots were adopted to reflect publication-bias and showed that the literature had missing areas of high statistical significance (right-hand side of the plots), suggesting no publication bias ( Figure 2G-I) . 
Further investigation and confirmation of results
Discussion
In the present study, we identified five studies that investigated the effects of miRNA-200b level on the WHO glioma grade. We found that miRNA-200b level was negatively associated with WHO glioma grade. However, no correlations were found between the miRNA-200b level and sex, age, tumor size, or extent of surgical resection. To our knowledge, this is the first meta-analysis to systematically estimate the relationship between miRNA-200b and the WHO glioma grade. 45  42  25  17  31  19  12  ------------49  110  69  41  156 97  59  100  56  44  166  110 56  66  42  24  200  124 76  45  42  27  15  38  21  17  ------------41  57  29  28  66  31  35  ------------47  42  24  18  46  29  17  47  28  19  41  25  16  31  19  12  57  34 10 Liu Q 2014 10 Liu AQ 2015 14 Liu AQ 2015 14 Liu AQ 2014 10 Liu AQ 2015 14 Li J 2015 12 Li J 2015 12 Li J 2015 Men DH 2014 13 Men DH 2014 13 Men DH 2014 13 Li J 2015 12 Men DH 2014 13 Men DH 2014 13 Wang We explored the correlation between miRNA-200b expression and the WHO glioma grade in 630 patients from five studies that investigated the pathologies in glioma specimens. We found that miRNA-200b was negatively correlated with higher WHO grades in patients with gliomas. Specifically, the pooled OR and 95% CI showed a significant negative correlation between miRNA-200b and WHO grade (n=5; OR, 0.070; 95% CI, 0.007-0.678; P=0.022). There were no significant correlations between miRNA-200b and sex (P=0.858), age (P=0.776), tumor size (P=0.134), or the extent of resection (P=0.778).
This finding that miR-200b is down-regulated in glioma is consistent with the findings reported by Peng et al. 21 They found an inverse correlation between the miR-200b level and CREB1 protein level. 21 MiR-200b directly targets the 3'-untranslated region of the CREB1 transcript and elicits specific and robust knockdown of CREB1 protein. 21 Hu et al 22 investigated the expression and function of LDHA in patients with gliomas. They found that LDHA was up-regulated in glioma specimens and that it promoted proliferation, invasion, and glycolysis in glioma cells. They also performed luciferase reporter assays and confirmed that LDHA was a direct target of miR-200b, the expression of which was inversely correlated with LDHA expression. 22 The results of the present meta-analysis are also consistent with the findings of our own study. In this study, we obtained frozen tissue samples of 87 glioma tissues and 41 normal brain tissues. The tumor samples were diagnosed by two pathologists who were blinded to the patient data. We adopted quantitative real-time PCR to measure the expression of miR-200b in glioma tissues and normal brain tissues (P<0.01). The results showed that the expression of miR-200b was significantly lower in gliomas than in normal tissues. Additionally, the miR-200b levels in grade I and II gliomas were much higher than those in grade III and IV gliomas (P<0.01). Our results further confirmed this association.
Limitations
Our meta-analysis should be interpreted within the context of its limitations. First, all included studies were performed in Asian populations. Patients of other races should be considered in future studies. Second, whether miRNA-200b represents an independent prognostic indicator beyond its ability to predict the WHO glioma grade remains unclear. A subgroup analysis of established glioma biomarkers, such as isocitrate dehydrogenase mutation, would be clinically meaningful. Third, the expression of other genes or noncoding RNAs that may interact with miRNA-200b should be considered. Fourth, it would be interesting, where possible from meta-analysis data, to verify whether miR-200b is a prognostic factor in terms of overall survival or disease-free survival of patients. An alternative strategy could be the use of data from the The Cancer Genome Atlas (TCGA), which will be our next work in future. Fifth, as is known, large quantities of miRNAs have been reported to be involved in gliomagenesis. More lines of evidence are needed to support our conclusions. And also, the signal-transducing mechanisms explaining roles of miR-200b in gliomagenesis are to be evaluated and verified in our next work. Finally, the cutoff points for miRNA-200b expression differed among the 15 reported that miRNA-141 could inhibit glioma cell growth and metastasis by targeting TGF-β2. Sun et al 23 recently investigated the expression level, clinicopathological significance, and prognostic significance of miR-429 in gliomas and found an increased miR-429 level (with ascending pathological grade) in glioma tissues compared with non-neoplastic brain tissues (P<0.01). Serna et al 24 showed that miRNA200c and E-cadherin expression are down-regulated while ZEB1 is up-regulated in glioblastomas with a high level of epidermal growth factor receptor (EGFR) amplification. Therefore, more studies are necessary to determine whether the significance of our results is specific to miRNA-200b.
